Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen

Hematological Malignancies Clinical Trial

Official title:
Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen

Status Terminated

Clinical Trial Summary

In this study, participants with high-risk hematologic malignancies undergoing hematopoietic cell transplantation (HCT), who do not have a suitable human leukocyte antigen (HLA)-matched related/sibling donor (MSD), matched unrelated donor (MURD) or killer-immunoglobulin receptors (KIR) ligand mismatched haploidentical donor identified, will receive a combined T cell depleted (TCD) haploidentical peripheral blood stem cell (PBSC) and unrelated umbilical cord blood transplantation (UCBT) using a total lymphoid irradiation (TLI) based preparative regimen.

Primary objective:

- To estimate the incidence of donor derived neutrophil engraftment by day +42 post-transplant for participants with high-risk hematologic malignancies undergoing a total lymphoid irradiation (TLI)-based hematopoietic cell transplantation (HCT) using a T cell depleted (TCI) haploidentical donor peripheral blood stem cell (PBSC) donor combined with an unrelated umbilical cord blood (UCB) donor.

Secondary objectives:

- Estimate the incidence of malignant relapse, event-free survival (EFS), and overall survival (OS) at one-year post-transplantation.

- Estimate the incidence and severity of acute and chronic graft versus host disease (GVHD) in the first 100 days after transplantation.

- Estimate the incidence of secondary graft failure transplant related mortality (TRM) and transplant related morbidity in the first 100 days after HCT.

Clinical Trial Description

Prior to stem cell infusion, participants will receive a preparative regimen of total lymphoid irradiation (TLI), fludarabine, cyclophosphamide, melphalan, and thiotepa to prepare their bone marrow. Thereafter, they will receive a hematopoietic cell graft from a haploidentical donor and an unrelated umbilical cord blood donor. Post-transplantation immunosuppressive treatment will include tacrolimus and mycophenolate mofetil. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02199041
Study type	Interventional
Source	St. Jude Children's Research Hospital
Contact
Status	Terminated
Phase	Phase 2
Start date	July 11, 2014
Completion date	May 23, 2017

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03248479` - Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies	Phase 1
Recruiting	`NCT05454241` - CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies	Phase 2
Recruiting	`NCT06041815` - Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological Malignancies
Active, not recruiting	`NCT05005442` - A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)	Phase 2
Recruiting	`NCT02300571` - Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant	N/A
Active, not recruiting	`NCT01428973` - Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens	Phase 2
Completed	`NCT00379587` - Rituximab for Prevention of Chronic GVHD	Phase 1/Phase 2
Terminated	`NCT00506948` - Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)	Phase 2
Completed	`NCT01162096` - Reduced Intensity Haploidentical Transplant for Hematological Malignancies	Phase 1/Phase 2
Active, not recruiting	`NCT04557098` - A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma	Phase 2
Recruiting	`NCT04283097` - Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects	Phase 1
Completed	`NCT03067155` - CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.	Phase 2
Completed	`NCT01725555` - A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors	Phase 1
Completed	`NCT00438178` - Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies	Phase 1
Completed	`NCT03711604` - Compassionate Use Study of Tenalisib (RP6530)	Phase 1/Phase 2
Withdrawn	`NCT01168882` - Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies	Phase 1
Completed	`NCT01246206` - Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT	Phase 2
Completed	`NCT01172132` - The Use of Intensive Care in Critically Ill Cancer Haematological Patients: "TRIAL-OH"	N/A
Completed	`NCT00506402` - A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies	Phase 1
Active, not recruiting	`NCT00163644` - RCT to Investigate Whether an Exercise Programme Improves the Physical Performance and QOL After BMT	N/A